『Biocon Launches Eylea Biosimilar Yesafili』のカバーアート

Biocon Launches Eylea Biosimilar Yesafili

Biocon Launches Eylea Biosimilar Yesafili

無料で聴く

ポッドキャストの詳細を見る
An interchangeable biosimilar to Eylea is launched in the US; patient enrollment is completed in two global phase 3 clinical trials evaluating Duravyu for diabetic macular edema; and Topcon receives CE mark for a fully automated ultra-widefield retinal slit scanner. Learn more about your ad choices. Visit megaphone.fm/adchoices
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません